Keywords: Abbott Labs, Teata Pharma. Licensing, Kidney disese, Bardoxolone

Abbott enters $450 million deal with Reata Pharma to gain rights to methyl for kidney disease outside USA

Article | 24 September 2010

Print This

US health care major Abbott Laboratories (NYSE: ABT) has signed a deal with Reata Pharmaceuticals to develop and commercialize bardoxolone ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in